Cancer deaths fall to historic low in UK

The latest stats on cancer death rates in the UK offer encouraging news – and further progress against the disease is within reach

The latest stats on cancer death rates in the UK offer encouraging news – and further progress against the disease is within reach

Good news: cancer death rates in the UK have fallen to their lowest level on record.

According to the latest statistics from Cancer Research UK, between 2022 and 2024 around 247 people per 100,000 died from cancer each year in the UK. This is down from a peak of 355 deaths per 100,000 in 1989 – a decline of nearly 29%. Researchers say the long-term drop reflects decades of investment in cancer research, prevention and treatment.

Much of this progress comes from major improvements in several common cancers. Over the past ten years, deaths from stomach cancer have fallen by 34%, while lung cancer deaths have dropped by 22%. Ovarian cancer deaths declined by 19%, breast cancer by 14% and prostate cancer by 11%.

These gains reflect several factors working together. Advances in cancer screening, a growing range of new and effective treatments, and earlier diagnosis have all played a role in improving survival.

In prostate cancer, for example, breakthroughs in hormone-based therapies have helped slow tumour growth. Perhaps the most dramatic improvement has been in cervical cancer , where deaths have fallen by 75% since the 1970s. This is largely due to national screening programmes and the introduction of the HPV vaccine.

A major driver of falling cancer deaths has been screening. The NHS cervical screening programme has been particularly effective, detecting cancers at very early stages, and often identifying pre-cancerous changes before cancer develops.

A major driver of falling cancer deaths has been screening. Image: Shutterstock

The success of the HPV vaccine, introduced in 2008 and now given to millions of people, has strengthened this progress by preventing infections that can trigger the cellular mutations leading to cervical cancer.

Screening has also improved outcomes in other cancers. Programmes for breast and colorectal cancer help detect disease earlier, when treatment is more likely to succeed. Similarly, the introduction of PSA testing has improved detection of prostate cancer.

At the same time, advances in cancer research have transformed treatment options. Targeted therapies and personalised medicine are increasingly common, allowing doctors to tailor treatment to the biology of an individual patient’s tumour. Hormone therapies that block testosterone, for instance, have significantly improved outcomes in prostate cancer.